Table 1.
Study population's demographic characteristics (N = 270)
| Characteristics | No. (%) |
|---|---|
| Sex | |
| Female | 205 (76.3%) |
| Age Groups | |
| 18-29 years | 39 (14.1%) |
| 30-39 years | 65 (24.1%) |
| 40-49 years | 85 (31.9%) |
| 50-59 years | 60 (22.2%) |
| 60-69 years | 19 (7.0%) |
| 70-79 years | 2 (0.7%) |
| Phenotype Distribution | |
| Clinically Isolated Syndrome (CIS) | 4 (1.5%) |
| Relapse-Remitting MS (RRMS) | 168 (62.2%) |
| Primary Progressive MS (PPMS) | 18 (7.0%) |
| Secondary Progressive MS (SPMS) | 10 (3.7%) |
| Patient unaware of his/phenotype | 70 (25.6%) |
| Median disease duration since diagnosis | 7 years [Interquartile range (IQR) = 9] |
| DMT efficacy | |
| Moderate efficacy1 | 121 (48.1%) |
| High efficacy2 | 98 (32.6%) |
| None of these | 51 (19.3%) |
| Employment | |
| Employed | 175 (64.8%) |
| Unemployed | 25 (9.3%) |
| Retired | 54 (20.0%) |
| Student | 16 (5.9%) |
| Literary Degree | |
| Primary School | 4 (1.5%) |
| Basic School | 14 (5.2%) |
| High School | 103 (37.8%) |
| Superior Degree | 125 (46.7%) |
| Professional Degree | 24 (8.9%) |
1
Beta interferon, dimethyl fumarate, glatiramer acetate and teriflunomide.
2
Cladribine, fingolimod, natalizumab, ocrelizumab, and rituximab.